PALB2 and familial pancreatic carcinoma: Another phase II clinical trial that evaluated the efficacy of single agent Veliparib in patients with BRCA or PALB2-mutated pancreatic cancer after first or second-line chemotherapy enrolled 16 patients with advanced disease and reported 1 unconfirmed PR, 4 patients with SD, 10 with progressive disease and 1 was not evaluable.